Raphael Clynes

Dr. Clynes is an internationally recognized cellular immunologist and medical oncologist. Dr. Clynes was on the faculty at the Columbia University where he developed several novel therapeutic approaches in cancer and autoimmunity. Since joining industry in 2014, Dr Clynes has led clinical immunotherapy development, including checkpoint inhibtors and novel CD3 bispecifics, at Bristol Myers Squibb (BMS) and at Xencor, where he is currently VP Translational Biology.

Dr. Clynes is an MIT graduate and MSKCC-trained medical oncologist. As a well-recognized expert in clinical immunology, Dr. Clynes has extensive prior experience as a contributing member of multiple scientific advisory boards in biopharma and review boards at international research foundations.